Specialty Chemicals

ABACHEM

ABACHEM released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 310.82 M, actual EPS CNY -0.1621

ABACHEM released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 303.59 M, actual EPS CNY -0.06

ABACHEM released FY2025 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 1.307 B, actual EPS CNY -0.1669

ABACHEM to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

ABACHEM to Release FY2025 Earnings Report on April 29 After-Market BJT

ABACHEM released FY2025 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 334.69 M, actual EPS CNY 0.0018

ABACHEM released FY2025 9 Months earnings on October 28 After-Market (BJT), actual revenue CNY 996.36 M, actual EPS CNY -0.0073

ABACHEM to Release FY2025 Q3 Earnings on October 29 After-Market (BJT)

ABACHEM released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 346.01 M, actual EPS CNY 0.0041

ABACHEM released FY2025 Semi-Annual earnings on August 26 After-Market (BJT), actual revenue CNY 661.67 M, actual EPS CNY -0.009

ABACHEM to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Yabanci Chemical Confirms Normal Operation of Pharmaceutical Intermediate Business

ABC Obtains Gold Award for Antibacterial Compound Synthesis Technology

Yabochem Discusses Pharmaceutical and Healthcare Business Cooperation with Guangzhou Pharmaceutical

Yabanci Chemical Reports 43.52% Revenue Growth in Q1 2025, Narrowing Net Loss Year-over-Year

ABACHEM released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 315.66 M, actual EPS CNY -0.0134

Yabangchem Inc. Reports Expanded Loss of 258 Million Yuan in 2024

Yabon Chemical Releases 2024 Annual Report

ABACHEM released FY2024 earnings on April 22 After-Market (BJT), actual revenue CNY 1.202 B, actual EPS CNY -0.2699

ABACHEM released FY2024 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 262.22 M, actual EPS CNY -0.216

300261

According to the Zhitong Finance APP, ABACHEM released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 996 million yuan, a year-on-year increase of 6.00%. The net loss attributable to shareholders of the listed company was 6.9164 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 24.8824 million yuan. The basic loss per share was 0.0072 yuan

Zhitong

ABACHEM released its performance for the first three quarters, with a net loss attributable to the parent company of 6.9164 million yuan

Recently, the board of directors of ABACHEM Co., Ltd. received a written resignation letter from senior management personnel Kang Litiao. Kang Litiao resigned from the position of deputy general manager for personal reasons and will not hold any position in the company after his resignation, which will take effect from the date the resignation letter is delivered to the board of directors. His original term was from 2025 to 2028. As of the announcement date, he did not hold any shares in the company and had no unfulfilled commitments

ABACHEM: Vice President Kang Litiao resigned for personal reasons

On September 18th, ABACHEM Co., Ltd. held a signing ceremony for a strategic cooperation agreement with Jiangsu Pesticide Research Institute Co., Ltd. at ABACHEM's Shanghai headquarters. The cooperation aims to promote the collaborative development of the local pesticide industry chain and accelerate the industrialization of innovative achievements

ABACHEM signs a strategic cooperation agreement with Soochow Research

601236

ABACHEM's controlling shareholder, Ningbo ABACHEM Holdings Co., Ltd., recently announced that it will extend the pledge of 37.97 million shares, with a pledge ratio of 14.73%. The pledgee is Hongta Securities, primarily for financing purposes. As of the announcement date, Ningbo ABACHEM and its concerted parties have pledged a total of 167.6 million shares, accounting for 48.28% of their shareholding. The company stated that the pledge risk is controllable and will not affect actual control and operations

Hongta Securities

ABACHEM's controlling shareholder has extended the pledge of some shares, and the overall risk is controllable

ABACHEM announced that its operating revenue in the first half of 2025 was 662 million yuan, a year-on-year increase of 12.31%. The net loss attributable to shareholders of the listed company was 8.6684 million yuan, compared to a net loss of 52.0136 million yuan in the same period last year

ABACHEM: Net loss of 8.6684 million yuan in the first half of 2025, a year-on-year decrease of 83.33%

600486

603639

301035

002942

603086

Debon Securities released a research report indicating that after the destocking of overseas inventories, the pesticide industry has seen a bottom rebound in prices, and the industry's prosperity is gradually recovering. It is expected that with the advancement of the "Rectifying Wind and Managing Volume" and "One Certificate, One Product" policies, the pesticide industry will enter a prosperous cycle. The report mentioned that the export demand for pesticides continues to improve, especially for exports to the United States and South America. Despite severe competition within the industry, it is expected that by the end of 2027, the market order will significantly improve, and product quality will enhance

Yangnong Chemical

hailir

RAINBOW CHEMICAL

Xinnong Chemical

Cynda

Debon Securities: The industry "anti-involution" has begun, optimistic about certain pesticide products with optimized patterns

01276

According to the Zhitong Finance APP, ABACHEM announced that the company has signed a "Supply Strategic Agreement" with HENGRUI PHARMA. The two parties have reached a framework agreement to establish a forward-looking strategic partnership aimed at jointly promoting technological innovation and quality upgrades of specific pharmaceutical intermediates and active pharmaceutical ingredients (API), enhancing the collaborative competitiveness of key links in the pharmaceutical industry chain, and achieving a win-win value in the field of advanced pharmaceutical manufacturing. This agreement will be effective for the long term, valid until July 31, 2035

HENGRUI PHARMA

ABACHEM signs supply strategic agreement with HENGRUI PHARMA

ABACHEM announced the termination of its plan to acquire Haotian Technology. The company originally planned to use its own funds or self-raised funds to acquire a portion of Haotian Technology's shares or subscribe to the newly registered capital to achieve control over Haotian Technology. After multiple rounds of negotiations, no agreement was reached on the core terms, and it was ultimately decided to terminate the investment matter

ABACHEM terminates the plan to acquire control of Haotian Technology

According to the Zhitong Finance APP, ABACHEM disclosed its performance forecast for the first half of 2025, expecting a net loss attributable to shareholders of the listed company of between 5 million and 10 million yuan; the net loss after deducting non-recurring gains and losses is expected to be between 17 million and 22 million yuan

ABACHEM issued a profit warning, expecting a net loss attributable to the parent company of 5 million to 10 million yuan in the first half of the year

ABACHEM stated in an institutional research that its subsidiary Nantong ABACHEM Co., Ltd. produces the chlorantraniliprole intermediate K acid using the CDMO model, with an annual production capacity of 2,000 tons. This product is currently supplied exclusively to a single customer and is not involved in market sales. The cooperation agreement with the customer is being renewed and a new agreement has not yet been formally signed. This model has not had a negative impact on the company's business, and future order changes need to be negotiated with the customer

ABACHEM: The company's chlorantraniliprole intermediate products adopt a CDMO model and do not participate in market competition

ABACHEM(300261.SZ)